Thermo Fisher aims to sell parts of its diagnostics business for $4bn
Deal would mark latest move by a life sciences group to jettison lower-growth assets
Related reading
Thermo Fisher nears $10bn takeover of drug trial software maker Clario
Deal for Nordic Capital-owned group would mark one of the biggest private equity exits of the year
Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences
Transaction continues a frenzy of M&A activity this year in the healthcare sector
MKS Instruments to offload $1bn chemicals unit to focus on chips
Supplier of semiconductor manufacturing equipment hopes to tap into artificial intelligence boom
Advent swoops for London-listed Spectris in £4.4bn deal
High-tech instruments maker says its board would be minded to recommend shareholders agree to a sale
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
Medline readies IPO in coming months in test of investor appetite
Offering seen as signal of whether large private equity groups can begin exiting largest deals